Loading...
Transition of Stable Pediatric Patients With Pulmonary Arterial Hypertension from Intravenous Epoprostenol to Intravenous Treprostinil
Intravenous epoprostenol was the first agent approved by the United States Food and Drug Administration for the management of pulmonary arterial hypertension (PAH). However, epoprostenol therapy carries the risks of a short half-life (<6 minutes) and side effects, including jaw pain, flushing, an...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2007
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1974790/ https://ncbi.nlm.nih.gov/pubmed/17317374 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.amjcard.2006.09.119 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|